Bevacizumab Biosimilar Approval China: NMPA Greenlights First Biosimilar
The NMPA has approved the first biosimilar of Bevacizumab, a groundbreaking step for cancer treatment accessibility in China.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 01, 2026
The National Medical Products Administration (NMPA) in China has granted its first NMPA bevacizumab approval for a biosimilar version of bevacizumab, a monoclonal antibody targeting VEGF. This approval is poised to broaden access to cancer treatment options within the APAC region, marking a significant advancement in the Chinese biosimilar regulatory landscape and potentially reducing treatment costs for patients.
Drug Overview
Bevacizumab (brand name not provided) is a monoclonal antibody that functions by inhibiting vascular endothelial growth factor (VEGF), a protein that promotes angiogenesis. By binding to VEGF-A, bevacizumab prevents it from activating VEGF receptors on endothelial cells, thereby inhibiting the formation of new blood vessels essential for tumor growth. It is primarily indicated for treating various solid tumors, including colorectal, lung, breast, and renal cancers.
Clinical Insights
Clinical development of bevacizumab biosimilars involves comprehensive analytical, pharmacokinetic, and clinical efficacy studies to demonstrate similarity to the originator product. These studies, including Phase I and Phase III trials, aim to confirm that there are no clinically meaningful differences in safety, purity, or potency between the biosimilar and the reference biologic. The primary endpoint in these trials is typically progression-free survival or overall response rate. Class-typical adverse events include hypertension, proteinuria, bleeding, thromboembolic events, and impaired wound healing. The safety profiles are expected to be consistent with the reference product, with no new safety signals identified.
Regulatory Context
The NMPA follows a stepwise approval pathway for biosimilars, including comprehensive analytical characterization, nonclinical studies, and clinical trials demonstrating biosimilarity. The process may take several years, with accelerated pathways available for products addressing unmet medical needs. Post-approval pharmacovigilance is required to monitor long-term safety.
Market Impact
The NMPA approval of a bevacizumab biosimilar introduces competition to the bevacizumab market in China, likely driving down costs and expanding patient access amid rising cancer incidence. This approval intensifies biosimilar competition in APAC and offers a cost-effective alternative to the originator bevacizumab with comparable efficacy and safety, supporting broader patient access in China. The target population includes patients with various solid tumors including colorectal, non-small cell lung, renal cell, and breast cancers, representing a large and growing cancer patient population in China with increasing healthcare expenditure.
Future Outlook
The approval of this bevacizumab biosimilar may pave the way for future label expansions to cover all indications of the reference product. The competitive landscape will likely evolve as more domestic and international biosimilar manufacturers enter the Chinese market.
Frequently Asked Questions
What is a bevacizumab biosimilar?
A bevacizumab biosimilar is a biologic product that is highly similar to the reference bevacizumab product, with no clinically meaningful differences in terms of safety, purity, and potency.
How does bevacizumab work?
Bevacizumab works by binding to VEGF-A, preventing it from activating VEGF receptors on endothelial cells, thereby inhibiting angiogenesis, which is critical for tumor growth.
What are the potential side effects of bevacizumab biosimilars?
Potential side effects are expected to be consistent with the reference product and include hypertension, proteinuria, bleeding, thromboembolic events, and impaired wound healing.
Why is the NMPA approval significant?
The NMPA approval marks a significant milestone in China's biosimilar regulatory landscape, potentially improving affordability and access to effective cancer treatments.
References
Asia-Pacific Editor
Dr. Yuki Tanaka is an oncologist specializing in Asian pharmaceutical markets and regulatory harmonization. Former PMDA reviewer with expertise in bridging studies and ethnic factors....
